CELU
Celularity Inc.
There isn't enough reported data to score CELU yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CELU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
CELU's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CELU PE Valuation
CELU has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CELU Forward outlook
There aren't enough analyst estimates for CELU to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CELU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.69 | +$1.48 |
| Q1 2026 | -$2.73 | -$0.28 |
| Q4 2025 | -$3.59 | -$0.95 |
CELU is still losing money, but far less than before: $1.69 per share over the past year, against $9.60 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CELU in the latest year-over-year earnings comparison.
CELU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.4M | -5.3% |
| Q1 2026 | $3.8M | -66% |
| Q4 2025 | $4.1M | -77% |
| Q3 2025 | $5.3M | -43% |
| Q2 2025 | $5.7M | -53% |
| Q1 2025 | $11.4M | -22% |
| Q4 2024 | $18.1M | +50% |
| Q3 2024 | $9.3M | +146% |
CELU's revenue has slid since its 2024 peak: $5M last quarter, down 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -78% | +199 points |
| Q1 2026 | -263% | -172 points |
| Q4 2025 | -537% | -486 points |
| Q3 2025 | -244% | -120 points |
| Q2 2025 | -277% | -193 points |
| Q1 2025 | -92% | -42 points |
| Q4 2024 | -51% | -161 points |
| Q3 2024 | -124% | +2498 points |
CELU's operating margin was −78% last quarter, up 199 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CELU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CELU on profitability, with a higher operating margin.
CELU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$5.1M | -432% |
| Q4 2024 | $1.5M | +$6.5M |
| Q3 2024 | -$179K | +$8.4M |
| Q2 2024 | -$3.5M | +$7.6M |
| Q1 2024 | -$4.4M | +$10.8M |
| Q4 2023 | -$4.9M | +$25.4M |
| Q3 2023 | -$8.6M | +$30.7M |
| Q2 2023 | -$11.1M | +$26.7M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with CELU at up 93%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
CELU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -955K shares |
| 1 year | +25% | +5.8M shares |
| 3 years | +89% | +13.8M shares |
| 5 years | +3561% | +28.5M shares |
CELU has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CELU Net Leverage
CELU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CELU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 6.1 | Oversold |
CELU's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CELU PE vs Healthcare Sector
| Metric | CELU | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CELU has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CELU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.13 | 40% below |
| 20 week MA | $1.04 | 35% below |
| 50 week MA | $1.12 | 39% below |
| 100 week MA | $1.63 | 58% below |
| 200 week MA | $2.85 | 76% below |
CELU is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CELU on trend strength, trading above more of its moving averages.
CELU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $99.5 | $118.0 | +19% |
| 2021 | $118.0 | $47.0 | -60% |
| 2022 | $47.0 | $11.5 | -76% |
| 2023 | $11.5 | $2.47 | -79% |
| 2024 | $2.47 | $2.24 | -9.3% |
| 2025 | $2.24 | $1.34 | -40% |
| 2026 YTD | $1.34 | $0.68 | -49% |
CELU has finished five years in a row lower, and it's down 49% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CELU on returns for 2026, with the stronger performance.